|Articles|March 1, 2023

Antimicrobial Stewardship Programs Can Reduce Consumption

Author(s)Rachel Lutz

Antimicrobial stewardship programs can protect drugs listed on the WHO Watch List, but the benefits are also dependent on countries' income level.

Antimicrobial stewardship programs can reduce the consumption of antimicrobials, including those on the WHO Watch List, in both hospital and non-hospital settings, according to a systematic review and meta-analysis published in JAMA Network Open.

Authors from around the Switzerland analyzed 52 studies that included more than 1.7 million patients in order to determine the association between antimicrobial stewardship programs and antibiotic use. The studies included in the meta-analysis included different health care and income settings, and were conducted between 2010 and 2020.

Overall, the study authors identified 19 prospective intervention studies, 12 randomized clinical trials, 10 quasi-experimental studies, 7 non-randomized controlled trials, and 4 retrospective cohorts. A majority of the studies were conducted in high-income countries, but 12 were conducted in low- or middle-income countries. The authors also noted that most of the studies were conducted in primary care sites (11) or tertiary care hospitals (32), though the remaining were conducted in general practitioner medical practices (3), ICUs (3), and nursing homes (3).

The common implementation methods for antimicrobial stewardship programs from the studies included:

  • Implementation of training guidelines (such as training health workers on treatment practices, AMR, and updating guidelines)
  • Decision support tools, which included electronic or paper algorithms that assisted with making treatment decisions
  • Antibiotic restrictions (preauthorization)
  • Prospective audit and feedback
  • Tracking, such as monitoring, documenting, and reporting prescription practices and infection resistance patterns
  • Pharmacy-based interventions
  • Microbiology-based interventions, such as antibiotic susceptibility tests to guide decisions

The study authors wrote that the latest published literature suggests that antimicrobial stewardship programs can reduce antibiotic consumption by 19% and the use of restricted antimicrobial drugs by 27% in hospital settings. But, they noted, little data exists around the effectiveness of antimicrobial stewardship programs in low- or middle-income countries (where antimicrobial use is exceptionally high, they said) compared to high-income countries.

In their own meta-analysis, the study authors suggested that antimicrobial stewardship programs were associated with a 10% reduction in antibiotic prescriptions and a 28% reduction in antibiotic consumption rates. They wrote that they observed reductions in consumption across all antibiotic classes, including: penicillin and β-lactamase inhibitor combinations, macrolides, fluoroquinolones, cephalosporins, and carbapenems.

The investigators also said that there was “good news” for antibiotics included on the WHO Watch list (drugs that have a particularly high risk of selection of bacterial resistance). With appropriate antimicrobial stewardship programs, the study authors said, these drugs can be protected.

Antimicrobial stewardship programs were responsible for reducing antibiotic prescriptions by 6% in high-income countries, the study authors said, which is also aligned with previous studies. They also observed significant reductions in prescriptions in low- and middle-income countries after antimicrobial stewardship program implementation, but the study authors cautioned that there were only a small number of studies that took place in these settings.

“Given the challenges involved with the implementation of antimicrobial stewardship programs in low- and middle-income countries, including often limited availability and access to antibiotics, unavailable diagnostics, and weak adherence to treatment, further research on how to best implement antimicrobial stewardship programs without compromising the quality of care provided to patients in low- and middle-income countries is urgently needed,” the study authors wrote.


Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.